Pharmaceutical Executive October 25, 2024
Under terms of the deal, Richter will receive an upfront cash payment of $25 million, along with potential future development, regulatory, and commercialization milestones.
AbbVie and Gedeon Richter announced a new collaboration to discover and develop novel targets for neuropsychiatric conditions. According to AbbVie, the new license agreement will expand upon close to two decades of partnering on central nervous system (CNS) projects, including globally launched products, such as Vraylar (cariprazine), and the discovery of investigational drug candidate, ABBV-932, for the treatment of bipolar depression and generalized anxiety disorder.1
“There remains a large unmet need for people living with neuropsychiatric disorders, making it imperative that we continue to innovate and pursue novel targets and approaches to discover and develop new...
Today's Sponsors
Today's Sponsor